文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

淋巴结阳性子宫及宫颈癌术后质子放疗的2期研究长期结果

Long-Term Results of a Phase 2 Study of Adjuvant Proton Radiation Therapy for Node-Positive Cancer of the Uterus and Cervix.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-03-13

质子治疗较光子放疗显著减少肠道、骨髓和肾脏受照体积,无野内复发,5年无进展生存76%、总生存80%,生活质量从基线至5年显著提高10.7分。

要点

  • 质子治疗较3DCRT和IMRT显著减少肠道、骨髓和肾脏受照体积(除V45膀胱和肠道外各剂量水平P<.05)。
  • 急性3级胃肠道毒性14%、晚期4.7%;无急性和晚期3级泌尿生殖毒性。
  • 2年和5年无进展生存分别为81%和76%,无野内复发;总生存分别为86%和80%。

核心结论

  • 质子治疗较光子放疗显著减少正常组织受照体积,在淋巴结阳性患者中似乎有效预防局部区域复发且急晚期毒性轻微。
  • 生活质量从基线至5年显著提高,平均增加10.7分(95%CI 0.9-20.4,P=.032)。

研究设计与样本

  • 患者接受45 Gy(RBE)分25次笔束扫描质子治疗(PBS-PT)。
  • 主要终点为PBS-PT与IMRT或3DCRT的剂量体积直方图和毒性比较,次要终点包括无进展生存、总生存、复发模式和生活质量。
  • 2013年10月至2018年10月完成放疗,中位随访60.6个月(范围11.2-68.8)。
  • 15例子宫癌、6例宫颈癌;4例接受盆腔放疗、17例接受扩大野放疗。

主要发现

  • 剂量体积直方图比较显示PBS-PT较3DCRT和IMRT在肠道、骨髓和肾脏的受照体积显著更少(所有P<.05),除V45膀胱和肠道外各剂量水平均如此。
  • 急性3级胃肠道毒性14%,晚期4.7%;急性和晚期3级泌尿生殖毒性均为0。
  • 急性3级血液学毒性24%,晚期4.7%;1例晚期3级淋巴水肿。
  • 2年和5年无进展生存分别为81%(95%CI 56%-92%)和76%(95%CI 51%-89%),无野内复发。
  • 2年和5年总生存分别为86%(95%CI 62%-95%)和80%(95%CI 55%-92%)。

关键数值与推荐

  • 质子治疗剂量为45 Gy(RBE)分25次。
  • 毒性按NCI CTCAE v4.02分级。
  • 生活质量采用FACT-En/Cx V4评估。

临床怎么用

  • 对于淋巴结阳性子宫或宫颈癌术后需盆腔和腹主动脉旁淋巴结照射的患者,PBS-PT可显著减少肠道、骨髓和肾脏受照体积。
  • 该方案似乎有效预防局部区域复发,急性和晚期3级毒性轻微。
  • 生活质量从基线至5年显著改善。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with node-positive (LN+) uterine or cervical cancer often require postoperative radiation therapy (RT) to the pelvis and para-aortic nodes. A prospective phase 2 study was conducted to evaluate the efficacy of proton beam RT for LN+ uterine or cervical cancer. METHODS AND MATERIALS: Patients with IIIC uterine and cervical cancer post hysterectomy and lymphadenectomy were eligible. Patients received 45 Gy(relative biological effectiveness) in 25 fractions with pencil beam scanning proton therapy (PBS-PT). Primary endpoints included comparing dose-volume histogram and toxicity (National Cancer Institute Common Terminology Criteria for Adverse Events v4.02) between PBS-PT and intensity modulated RT or 3-dimensional conformal RT. Secondary endpoints included progression-free survival, overall survival, patterns of recurrence, and quality of life (QOL using Functional Assessment of Cancer Therapy-Endometrial/Cervix Version 4, FACT-En/Cx V4). RESULTS: Twenty-one patients completed RT between October 2013 and October 2018. Median follow-up was 60.6 months (range, 11.2-68.8). There were 15 uterine and 6 cervical cancer patients. Four received pelvic and 17 received extended-field RT. Dose-volume histogram comparisons showed significantly less volume treated with PBS-PT compared to 3-dimensional conformal RT and intensity modulated RT for bowel, bone marrow, and kidney (all P < .05) at all dose levels except V45 bladder and bowel. Acute and late grade 3 gastrointestinal toxicity were 14% and 4.7%, respectively. There were no acute or late grade 3 genitourinary toxicities. Acute and late grade 3 hematologic toxicities were 24% and 4.7%, respectively. There was 1 late grade 3 lymphedema. The 2- and 5-year progression-free survival were 81% (95% CI, 56%-92%) and 76% (95% CI, 51%-89%). There were no in-field recurrences. The 2- and 5-year overall survival were 86% (95% CI, 62%-95%) and 80% (95% CI, 55%-92%). QOL increased significantly over time with an average increase of 10.7 points from baseline to 5 years (95% CI, 0.9-20.4, P = .032). CONCLUSIONS: Compared to photon RT, PBS-PT treats significantly less normal tissue volume. PBS-PT appears effective in preventing local-regional recurrence in LN+ patients with minimal acute and late toxicity. QOL significantly improved from baseline to 5 years.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Russo AL, Depauw N, Horick NK, et al. Long-Term Results of a Phase 2 Study of Adjuvant Proton Radiation Therapy for Node-Positive Cancer of the Uterus and Cervix. Int J Radiat Oncol Biol Phys. 2025. PMID: 40089072. doi:10.1016/j.ijrobp.2025.03.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。